Regulatory mechanisms and fibrolysis

Regulatory Mechanisms and Fibrinolysis

 

 

·       The Hemostatic System- Initiation & Propagation

·       Regulator mechanisms

·       Fibrinolysis

 

The Hemostatic System: Initiation and Propagation

•       Pathways are not distinct, independent – actually interdependent.

•       Normal coagulation requires

o   Cells that express TF (usually extravascular)

o   Platelets, usually intravascular

•       2 Phases

o   Initiation______________________

§  Occurs on TF expressing cells

§  3-5% thrombin

o   Propagation_______________________

§  Occurs on platelets

§  95% or more of thrombin

Initiation

•       Begun by formation of extrinsic tenase complex (VIIa, TF, +Ca++, phospholipids)

•       Generation of small amounts of thrombin

•       Less efficient than intrinsic tenase complex

o   But platelets, cofactors and procoagulants become activated

 

•       Low level of thrombin generated in the initiation:

(1) activates platelets through cleavage of protease activated receptors PAR-1 and PAR-4

(2) activates factor V released from platelet a-granules

(3) activates factor VIII and dissociates it from VWF

(4) activates factor XI, the intrinsic accessory procoagulant that activates more factor IX

(5) Splits fibrinogen peptides A and B from fibrinogen and forms a preliminary fibrin network. The initial platelet plug is thus formed.



Propagation

•       More than 95% of thrombin generation

•       Occur on the surface of activate platelet

•       Large number of platelets adhere to site of injury

o   By low levels of thrombin______________ (initiation)

o   Adhering to exposed collagen

o   This creates COAT platelets (collagen and thrombin)

•       COAT Platelets

o   higher level of procoagulant activity than platelets exposed to collagen alone

o   provide a surface for formation and amplification of complexes____________

o   Both platelets and tissue factor-bearing cells are essential for physiologic coagulation

o   Deficiencies of key proteins (VII, IX, VIII, X, V, or prothrombin) compromise thrombin generation and manifest as significant bleeding disorders

 

 

Coagulation Regulatory Mechanisms

•       Balance between procoagulant & anticoagulant systems.

•       Activated factors and/or platelets must be kept at the site of injury so fibrin formation is limited to the site of vascular injury

•       Factors and platelets must be controlled so they are inactive when distant from a site of vessel damage and blood remains fluid in uninvolved vessels.

 

Principle Regulators

Tissue Factor Pathway Inhibitor (TFPI)

Antithrombin (AT)

Activated protein C (APC)

 

 

Tissue Factor Pathway Inhibitor (TFPI)

•       TFPI is synthesized primarily by ECs and is also expressed on platelets

•       Binds to and inhibits

o   Factor Xa_____________

o   VIIa:TF complex

•       2 Step Process

o   First TFPI binds factor Xa and inactivates it

o   then TFPI:Xa complex binds and inactivates TF: VIIa, preventing more activation of Xa.

•       Alternatively, TFPI may _____bind directly________ to Xa and VIIa in the TF:VIIa:Xa complex

 

 

 

 

Protein C Regulatory System

•       Thrombin cleaves fibrinogen generating a fibrin clot

o   activates factors _____V, VIII, XI, XIII_________

o   Propagating more thrombin generation

•       In intact normal vessels

o   thrombin avidly binds thrombomodulin

o   triggers ____protein C regulatory system_________

§  revises thrombin’s function from a procoagulant enzyme to an anticoagulant.

•       EC protein C receptor (ECPR)

o   transmembrane protein

o   binds protein C adjacent to the thrombomodulin-thrombin complex.

o   augments the action of thrombin-thrombomodulin at least fivefold

•       Activated protein C (APC)

o   Dissociates from EPCR and binds its cofactor, free plasma protein S.

o   stabilized APC-protein S complex hydrolyzes and inactivates factors

§  Va and VIIIa

§  slowing or blocking thrombin generation and coagulation.

•       Protein S

o   cofactor that binds and ___stabilizes APC_____________________

o   synthesized the liver and circulates in the plasma in two forms:

§  40% of protein S is free

§  60% is covalently bound to complement control protein C4b-binding protein (C4bBP)

o   bound protein S _____cannot participate_________ in the protein C anticoagulant

o   free plasma protein S can serve as the APC

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Antithrombin (AT)

 

•       serine protease inhibitor (serpin)

•       binds and neutralizes serine proteases

o   thrombin

o   Ixa

o   Xa

o   XIa

o   XIIa

o   Prekallikrein

o   Plasmin

•       requires ___heparin____________ for effective anticoagulant activity.

o   available from endothelium-associated mast cell granules or as EC heparan sulfate.

•       AT’s amplified 2000-fold by binding to heparin

•       Heparin induces a conformational change in the AT molecule

o   allows binding of activated coagulation factors, causes inactivation

•       Inhibition of thrombin, factor X, and other serine proteases by AT is dependent on:

o   _____length______________ of the heparin chain

o   Longer heparin chains are able to bind both molecules to produce inhibition of thrombin

 

 

 

 

 

 

 

 

 

Heparin Cofactor II (HCII)

•       2nd line inhibitor of thrombin

•       primarily targets thrombin

•       requires heparin

Other SERPINS

•       ZPI

•       protein C inhibitor

•       a1-protease inhibitor (a1-antitrypsin)

•       a2-macroglobulin

•       a2-antiplasmin

•       PAI-1

 

 

 

Fibrinolytic System

•       Activation of coagulation also activates ________fibrin lysis_____________.

•       Removal of unwanted fibrin deposits by bound plasmin.

•       Re-establishes blood flow and facilitates the healing process

•       Two activators of fibrinolysis

o   ___tissue plasminogen activator_______ (TPA)

o   Urokinase plasminogen activator (UPA),

§  Convert fibrin-bound plasminogen into plasmin

·       the principle enzyme of the fibrinolytic system

•       delicate balance between the activators and inhibitors in this system.

 

 

Plasminogen

•       Plasmin is a serine protease that systematically digests fibrin polymer

•       Synthesized by the liver__________.

•       Circulates as a zymogen.

•       Plasminogen is activated to plasmin by tissue plasminogen activator (tPA), urokinase, or other endogenous activators:

o   Factor XIa, XIIa fragments, Kallikrein, HMMK

•       FDPs: fibrin degradation products – x, y, d, e, D-dimer

•        

 

 

 

 

Plasmin

•       Bound plasmin digests clots and restores blood vessel patency.

•       free plasmin can be found in the circulation

•       capable of digesting plasma fibrinogen, factor V, factor VIII, and fibronectin.

 

Tissue Plasminogen Activator (TPA)

•       ECs secrete TPA

o   hydrolyzes fibrin-bound plasminogen

o   converting it to ___plasmin____________

o   initiating fibrinolysis

•       Circulating TPA is bound to inhibitors such as PAI-1

o   complexes are cleared from circulation

•       synthetic recombinant TPAs

o   mimic natural TPA

o   “clot-busting”

 

Urokinase Plasminogen Activator

•       Secreted in urinary tract epithelial cells, monocytes, and macrophages

•       Doesn’t bind to fibrin

•       Becomes incorporated into the mix of fibrin-bound plasminogen and TPA at the time of thrombus formation

•       Intrinsic plasminogen activator

•       Small amounts circulate in the plasma and thus it plays a minor role in in-vivo fibrinolysis.

•       Purified urokinase preparations are widely used to dissolve clots

 

Plasminogen Inhibitors

 

Plasminogen activator inhibitor-1 (PAI-1)

•       Principle inhibitor of plasminogen

§  Inactivate ____TPA and UPA_________________

•       is produced by ECs, megakaryocytes, smooth muscle cells, fibroblasts, monocytes, adipocytes, hepatocytes, and other cell types

•       Behaves as an acute phase reactant protein.

§  Increased after major surgery, MI and severe trauma.

•       Increased PAI-1 levels correlate with reduced fibrinolytic activity and increased risk of thrombosis

 

 

Plasmin inhibitors

Alpha 2 antiplasmin

•       Main inhibitor of plasmin and therefore the fibrinolytic system.

•       Interferes with absorption of plasminogen to fibrin.

•       Same binding site as fibrin therefore the plasmin absorbed onto fibrin is protected from the action.  Only free, circulating plasmin is attacked

 

 

 

 

Fibrinolysis by plasmin

 

•       Proteolytically degrades both ____fibrin and native fibrinogen_____ in circulation.

•       Products termed fibrin/fibrinogen degradation products (FDPs)

§  Fragment X (still capable of clotting).

§  Fragment X into Fragment Y + Fragment D

§  Fragment Y into Fragment D + Fragment E

§  Result = 2 D’s and 1 E

•       D-Dimer specific to fibrin degradation (to rule out DIC, DVT, PE)

 

Fibrin Degradation Products FDPs

•       Interfere with further thrombin–induced fibrin formation and increase vascular permeability

•       Degrade V, VIII, XIIa, fibrinogen, fibrin, and GP1b

•       Cleave C3 into fragments and activate  complement

 

 

 

 

 

Kinin System

•       Important in inflammation, ______vascular permeability__________, and chemotaxis

•       Involved in contact activation of intrinsic pathway

o   Prekallekrein circulates complexed to HMWK

o   XIIa (+HMWK) activates prekallekrein to kallekrein and XI to XIa

o   Kallekrein and XIa then reciprocally activate XII to XIIa in a feedback system that amplifies the reaction

•       Kallekrein

o   An enzyme, also activates plasminogen to plasmin

o   Acts on HMWK to release ____bradykinin________________

§  Increase vascular permeability

§  Contract smooth muscle

§  Dilate small blood vessels

§  Induce inflammation and pain

§  Release prostaglandins from tissues